163 related articles for article (PubMed ID: 8505151)
1. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
Semmler J; Wachtel H; Endres S
Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
[TBL] [Abstract][Full Text] [Related]
3. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
6. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
[TBL] [Abstract][Full Text] [Related]
7. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
8. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
11. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
[TBL] [Abstract][Full Text] [Related]
12. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice.
Liang L; Beshay E; Prud'homme GJ
Diabetes; 1998 Apr; 47(4):570-5. PubMed ID: 9568689
[TBL] [Abstract][Full Text] [Related]
13. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
[TBL] [Abstract][Full Text] [Related]
15. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
Sullivan GW; Carper HT; Mandell GL
Int J Immunopharmacol; 1995 Oct; 17(10):793-803. PubMed ID: 8707444
[TBL] [Abstract][Full Text] [Related]
16. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis.
Eigler A; Greten TF; Sinha B; Haslberger C; Sullivan GW; Endres S
Scand J Immunol; 1997 Feb; 45(2):132-9. PubMed ID: 9042424
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Badger AM; Olivera DL; Esser KM
Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
[TBL] [Abstract][Full Text] [Related]
18. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis.
Sommer N; Löschmann PA; Northoff GH; Weller M; Steinbrecher A; Steinbach JP; Lichtenfels R; Meyermann R; Riethmüller A; Fontana A
Nat Med; 1995 Mar; 1(3):244-8. PubMed ID: 7585041
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT.
Navarro J; Punzón C; Jiménez JL; Fernández-Cruz E; Pizarro A; Fresno M; Muñoz-Fernández MA
J Virol; 1998 Jun; 72(6):4712-20. PubMed ID: 9573235
[TBL] [Abstract][Full Text] [Related]
20. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
